Stifel Financial Corp Makes New $96,000 Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,460 shares of the biopharmaceutical company’s stock, valued at approximately $96,000.

A number of other hedge funds and other institutional investors have also modified their holdings of EBS. Jacobs Levy Equity Management Inc. acquired a new position in Emergent BioSolutions during the third quarter worth $1,547,000. Hilltop Holdings Inc. increased its holdings in shares of Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 12,515 shares during the last quarter. FORA Capital LLC bought a new position in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $103,000. FMR LLC lifted its holdings in Emergent BioSolutions by 12.6% in the 3rd quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,446 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in Emergent BioSolutions during the third quarter worth approximately $141,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Trading Up 11.9 %

Shares of Emergent BioSolutions stock opened at $9.25 on Tuesday. Emergent BioSolutions Inc. has a 1 year low of $1.42 and a 1 year high of $15.10. The company’s fifty day simple moving average is $9.19 and its 200-day simple moving average is $8.91. The company has a market cap of $501.20 million, a price-to-earnings ratio of -2.26 and a beta of 1.59. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th. HC Wainwright initiated coverage on shares of Emergent BioSolutions in a report on Monday. They issued a “buy” rating and a $15.00 target price on the stock. StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Benchmark raised their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.